BriefHealth
Costco will provide Medicare Advantage plans and a Medicare supplemental plan
T
Read full storyThe Independent
Original source
Trending
Pakistan arrests man hunted by US over $126m postage fraud caseMore than S$45 million set aside to help Singapore manufacturers adopt AIVoice actor Hiroshi Tsuchida, star of Attack On Titan and Kakuranger, dies at age 54Up close with Scuderia Ferrari HP: A special raceCOTU lauds Ruto's move on PAYE reliefs for Kenyans earning under Ksh.32KActor Onyi admitted to NACADA centre for threePakistan arrests man hunted by US over $126m postage fraud caseMore than S$45 million set aside to help Singapore manufacturers adopt AIVoice actor Hiroshi Tsuchida, star of Attack On Titan and Kakuranger, dies at age 54Up close with Scuderia Ferrari HP: A special raceCOTU lauds Ruto's move on PAYE reliefs for Kenyans earning under Ksh.32KActor Onyi admitted to NACADA centre for three
Related Stories
Health6h ago
She pioneered breast care nursing in Singapore and, at 74, still cares for breast cancer patients
After establishing breast care services at Singapore General Hospital in 1992, Nagalingam Saraswathi trained nurses from other hospitals and started a support group for breast cancer patients. More than three decades later, caring for them remains a huge part of her life.
CChannel Newsasia
Health12h ago
Re: Renal outcomes in people with type 2 diabetes with and without albuminuria treated with SGLT-2 inhibitors and GLP-1 receptor agonists: target trial emulation
Agreement: I Agree Body: Dear Editor Turchin et al. conducted a prospective study to evaluate the risk of renal deterioration in people with type 2 diabetes, who were prescribed glucagon-like peptide-1 (GLP-1) receptor agonists or sodium-glucose contransporter-2 (SGLT-2) inhibitors as an additional drug (1). The authors paid special attention to the existence of albuminuria (albumin to creatinine ratio ≥30 mg/g). Compared with DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors significantly reduce the risk of deterioration of renal function in people with albuminuria. In contrast, there was no advantage of renal benefit in people without albuminuria. I present my comment. Lee et al. reported the difference in the ability of renal protection and survival in patients with type 2 diabetes, who received SGLT-2 inhibitors or GLP-1 receptor agonists (2). They concluded that SGLT-2 inhibitors presented lower risk in the progression to kidney replacement therapy than GLP-1 receptor agonists. This means that the choice from two therapies is important for preventing the risk of renal deterioration in patients with type 2 diabetes. In combination with existence of proteinuria, risk assessment should be conducted by separating SGLT-2 inhibitors or GLP-1 receptor agonists as an additional drug. References 1. Turchin A, Petito LC, Hegermiller E, et al. Renal outcomes in people with type 2 diabetes with and without albuminuria treated with SGLT-2 inhibitors and GLP-1 receptor agonists: target trial emulation. BMJ 2026;394:e100574. 2. Lee YC, Wu LC, Wu VC, et al. Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists and Sodium/Glucose Cotransporter 2 Inhibitors in Preventing Chronic Kidney Failure and Mortality in Patients With Type 2 Diabetes and CKD. Am J Kidney Dis 2025;86(3):301-313.e1. No competing Interests: Yes The following competing Interests: Electronic Publication Date: Tuesday, October 20, 2026 - 00:08 AI use: No, I have not used AI Highwire Comment Subject: Renal outcomes in people with type 2 diabetes with and without albuminuria treated with SGLT-2 inhibitors and GLP-1 receptor agonists: target trial emulation Workflow State: Released Full Title: Re: Renal outcomes in people with type 2 diabetes with and without albuminuria treated with SGLT-2 inhibitors and GLP-1 receptor agonists: target trial emulation Highwire Comment Response to: Renal outcomes in people with type 2 diabetes with and without albuminuria treated with SGLT-2 inhibitors and GLP-1 receptor agonists: target trial emulation Check this box if you would like your letter to appear anonymously:: Last Name: Kawada First name and middle initial: Tomoyuki Email: kawada@nms.ac.jp Address: 1-1-5 Sendagi, Bunkyo-ku, Tokyo, Japan Occupation: Proressor Emeritus Affiliation: Nippon Medical School BMJ: Additional Article Info: Rapid response
BBmj
Health6h ago
Nigeria confirms Ebola case linked to East Africa
A female patient is in isolation and receiving medical care after being admitted to a hospital in Abuja.
TThe Bbc
Brief
Health6h ago
Health authorities dismiss reports of insulin shortage, cite unavailability of one brand
Officials say alternatives for the unavailable brand remain available in local markets.
DDawn